title: Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients.
abstract: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with few therapeutic options. Recently, insight into cancer biology suggested abnormal lipid metabolism to be a risk factor for human malignancies. As a key enzyme implicated in lipid metabolism, PLD1 was elevated in various human cancer associating with malignant phenotypes. However, little was known about its expression and function in PDAC. We showed that PLD1 was elevated in both the cell lines and clinical samples of PDAC, and it positively correlated with vascular invasion (p = 0.041) and responsible for a poor prognosis (p = 0.009). Meanwhile, we also found Sp1 to be elevated in the disease, correlating with vascular invasion (p = 0.007). Moreover, the correlation assay suggested that PLD1 positively correlated with Sp1 in the clinical sample (r = 0.390; p < 0.001) and the cell lines. Finally, we showed that co-high expression of both the factors confers the poorest prognosis for the patients, and that their simultaneous high expression might be an independent prognostic factor (p = 0.001; HR = 3.427; 95% CI 1.629-7.211).
authors.affiliation: Department of Medical Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, China.|Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Jiong
authors.initials: J
authors.lastname: Hu
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Hai
authors.initials: H
authors.lastname: Hu
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Hang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Dong-Hui
authors.initials: DH
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, China.|Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China.
authors.forename: Li-Wei
authors.initials: LW
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010739:Phospholipase D / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D016329:Sp1 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D016329:Sp1 Transcription Factor; C108209:SP1 protein, human; D010739:Phospholipase D; C106801:phospholipase D1
keywords: PDAC; PLD1; Sp1; immunohistochemistry; prognosis